Argenx to Present at Upcoming Investor Conferences
Argenx to Present at Upcoming Investor Conferences
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker, globally in the U.S., Japan, Israel, the EU, the UK, China and Canada. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit and follow us on LinkedIn, X/Twitter, Instagram, Facebook, and YouTube.November 26, 2024
Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following upcoming investor conferences in December.
2024年11月26日
荷兰阿姆斯特丹——致力于改善严重自身免疫性疾病患者生活的全球免疫学公司argenx（泛欧交易所和纳斯达克股票代码：ARGX）今天宣布，管理团队成员将参加以下即将在12月举行的投资者会议。
-
Citi's 2024 Global Healthcare Conference. Fireside chat on Tuesday, December 3 at 1:45 p.m. ET in Miami, FL.
-
7th Annual Evercore I&I HealthCONx Conference. Fireside chat on Wednesday, December 4 at 1:45 p.m. ET in Coral Gables, FL.
-
Piper Sandler's 35th Annual Healthcare Conference. Fireside chat on Thursday, December 5 at 9:00 a.m. ET in New York, NY.
- 花旗2024年全球医疗保健会议。美国东部时间12月3日星期二下午 1:45 在佛罗里达州迈阿密举行的炉边谈话。
- 第七届年度 Evercore I&I HealthConx 会议。美国东部时间12月4日星期三下午 1:45 在佛罗里达州科勒尔盖布尔斯举行的炉边谈话。
- 派珀·桑德勒的第 35 届年度医疗保健会议。美国东部时间12月5日星期四上午9点在纽约州纽约的炉边谈话。
Additional information regarding these events will be available on the Investors section of the argenx website at argenx.com/investors.
有关这些活动的更多信息将在argenx网站的投资者栏目argenx.com/investors上公布。
About argenx
关于 argenx
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker, globally in the U.S., Japan, Israel, the EU, the UK, China and Canada. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit and follow us on LinkedIn, X/Twitter, Instagram, Facebook, and YouTube.
argenx 是一家全球免疫学公司，致力于改善患有严重自身免疫性疾病的人的生活。argenx通过其免疫学创新计划（IIP）与领先的学术研究人员合作，旨在将免疫学突破转化为世界一流的新型抗体药物组合。argenx在美国、日本、以色列、欧盟、英国、中国和加拿大开发了第一款获得批准的新生儿Fc受体（FcRn）阻滞剂，并正在全球商业化。该公司正在评估埃夫加替莫德在多种严重的自身免疫性疾病中的应用，并在其治疗特许经营范围内推进几种早期实验药物。欲了解更多信息，请在领英、X/推特、Instagram、脸书和YouTube上访问并关注我们。
For further information, please contact:
欲了解更多信息，请联系：
Media:
媒体：
Ben Petok
bpetok@argenx.com
本·佩托克
bpetok@argenx.com
Investors:
投资者：
Alexandra Roy (US)
aroy@argenx.com
亚历山德拉·罗伊（美国）
aroy@argenx.com
Lynn Elton (EU)
lelton@argenx.com
林恩·埃尔顿（欧盟）
lelton@argenx.com
